(NASDAQ: DSGN) Design Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 80.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.89%.
Design Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast DSGN's revenue for 2029 to be $1,363,338,136, with the lowest DSGN revenue forecast at $1,363,338,136, and the highest DSGN revenue forecast at $1,363,338,136. On average, 1 Wall Street analysts forecast DSGN's revenue for 2030 to be $4,318,945,876, with the lowest DSGN revenue forecast at $4,318,945,876, and the highest DSGN revenue forecast at $4,318,945,876.
In 2031, DSGN is forecast to generate $7,542,779,289 in revenue, with the lowest revenue forecast at $7,542,779,289 and the highest revenue forecast at $7,542,779,289.